Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size & Share, by Type (Bronchodilators, Antibiotics), End User (Hospitals, Homecare, Research Institutes) - Global Supply & Demand Analysis & Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5523
  • Published Date: Jan 11, 2024
  • Report Format: PDF, PPT

Companies Dominating the COPD Treatment Market

top-features-companies
    • GlaxoSmithKline plc
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • AstraZeneca plc
    • Boehringer Ingelheim International GmbH
    • Novartis International AG
    • Teva Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Merck & Co., Inc.
    • Sunovion Pharmaceuticals Inc.
    • Chiesi Farmaceutici S.p.A.
    • Circassia Pharmaceuticals plc

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • AstraZeneca announced the acquisition of Caelum Biosciences, a US-based biotech developing novel medicines for chronic respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). This acquisition strengthens AstraZeneca's respiratory franchise and broadens their pipeline with promising late-stage assets.
  • AstraZeneca and Merck announced a collaboration for a Phase 3 clinical trial evaluating Lynparza® (olaparib), a targeted therapy, in combination with gemcitabine and nab-paclitaxel for the treatment of patients with metastatic pancreatic cancer harboring BRCA mutations. This partnership seeks to expand treatment options for this aggressive cancer with limited therapeutic options.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5523
  • Published Date: Jan 11, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing demand for healthcare sector is the major factor driving the market growth.

The market size of chronic obstructive pulmonary disease treatment is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2024-2036.

The major players in the market GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim International GmbH, Novartis International AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying